Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin gamma Fc receptor I, commonly known as CD64 or FCGR1A, is a high-affinity receptor for the Fc region of immunoglobulin G (IgG). It plays a crucial role in both innate and adaptive immune responses by mediating various effector functions upon binding to IgG-coated targets such as pathogens or immune complexes. CD64 is constitutively expressed on monocytes and macrophages, and inducible on neutrophils and eosinophils during inflammatory conditions. Upon ligand binding (i.e., cross-linking by IgG), CD64 transduces signals through ITAM motifs present on its associated γ-chain, leading to cell activation including phagocytosis or cytokine production. Targeting CD64 may enhance or suppress immune responses depending on context, with potential applications in improving monoclonal antibody therapies or treating autoimmune diseases.
Modulation of immune response through enhancement or suppression of CD64 activity by glycan recognition mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin Gamma Fc Receptor I (CD64).